In addition, peptides derived from TERT have been in focus in anti-cancer immunotherapy—either to raise CD8+ cytotoxic T cell responses against TERT-epitopes on tumor cells [62] or to monitor tumor-specific anti-telomerase-specific CD4+ T cell immunity to TERT-neoantigens before and after chemo-or immunotherapy (Telocap02, NCT02846103). This evidence concerns the gene TERT and neoplasm.